Ekso Bionics - EKSO Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year target prices for Ekso Bionics' shares. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 696.5% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.

Ekso Bionics' stock was trading at $2.65 at the start of the year. Since then, EKSO stock has decreased by 57.4% and is now trading at $1.13.
View the best growth stocks for 2022 here.

Ekso Bionics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 49,000 shares, a drop of 20.3% from the October 31st total of 61,500 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is presently 1.6 days. Currently, 0.4% of the company's shares are short sold.
View Ekso Bionics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EKSO earnings forecast.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings results on Monday, November, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. The business earned $3.05 million during the quarter, compared to the consensus estimate of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same quarter in the previous year, the business earned ($0.52) EPS.

Ekso Bionics's stock reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include OrganiGram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics' stock is owned by a number of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (2.43%), Citadel Advisors LLC (0.00%), Strategic Wealth Investment Group LLC (0.17%) and Dimensional Fund Advisors LP (0.14%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends.

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EKSO stock can currently be purchased for approximately $1.13.

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $14.85 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.